<p>根据 Danske Bank A S 最近向证券交易委员会（SEC）提交的 13F 文件，该银行在 2023 年第四季度减少了对 Exelixis, Inc.（NASDAQ:EXEL - 免费报告）股票的持有量，减少幅度达到 99.4%。在该季度出售了 234,545 股后，Danske Bank A S 目前持有该生物技术公司 1,500 股股票。Danske Bank A S 在 Exelixis 的持股在最近一个季度末的价值为 66,000 美元。</p>
<ul>
<li>Exelixis 报告了稳健的收益——新的高点是否回归？</li>
</ul>
<p>其他几家机构投资者和对冲基金最近也买卖了 EXEL 的股票。Richardson Financial Services Inc.在第三季度将其在 Exelixis 的持股增加了 95.1%。Richardson Financial Services Inc.目前拥有 599 股该生物技术公司的股票，价值 25,000 美元，此前在上个季度又购买了 292 股。Anchor Investment Management LLC 在第三季度将其在 Exelixis 的持股增加了 500.0%。Anchor Investment Management LLC 目前拥有 600 股该生物技术公司的股票，价值 25,000 美元，此前在上个季度又购买了 500 股。Root Financial Partners LLC 在第三季度获得了 Exelixis 的新股份，价值约 28,000 美元。Activest Wealth Management 在第四季度获得了 Exelixis 的新股份，价值约 32,000 美元。最后，Northwestern Mutual Wealth Management Co.在第三季度将其在 Exelixis 的持股增加了 1,380.4%。Northwestern Mutual Wealth Management Co.目前拥有 829 股该生物技术公司的股票，价值 34,000 美元，此前在上个季度又购买了 773 股。对冲基金和其他机构投资者持有该公司 85.27% 的股票。</p>
<h2>Exelixis 的内部交易</h2>
<p>在相关消息中，SVP Brenda Hefti 于 2 月 18 日星期三出售了 18,669 股该公司的股票。股票以平均价格 44.01 美元出售，总价值为 821,622.69 美元。出售完成后，该高级副总裁直接持有 96,512 股公司股票，价值约 4,247,493.12 美元。此次交易使其持股减少了 16.21%。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过此链接获取。此外，CFO Christopher J. Senner 于 2 月 17 日星期二出售了 30,617 股该公司的股票。股票以平均价格 43.67 美元出售，总价值为 1,337,044.39 美元。出售完成后，该首席财务官持有 976,092 股公司股票，价值约 42,625,937.64 美元。此次交易使其持股减少了 3.04%。该出售的披露信息可在 SEC 文件中找到。在上个季度，内部人士共出售了 362,849 股公司股票，价值 15,917,463 美元。目前公司内部人士持有 2.60% 的股票。</p>
<h2>华尔街分析师的看法</h2>
<ul>
<li>如果有的话，3 只股票适合购买以应对软着陆</li>
</ul>
<p>EXEL 已成为几份研究报告的主题。Stifel Nicolaus 在周三将 Exelixis 的目标价从 44.00 美元上调至 47.00 美元，并给予该公司 “持有” 评级。Weiss Ratings 在 1 月 22 日的报告中重申了对 Exelixis 的 “买入（b）” 评级。Truist Financial 在 4 月 27 日的报告中将 Exelixis 的评级上调至 “强力买入”。Barclays 在 4 月 20 日的报告中将 Exelixis 的目标价从 44.00 美元上调至 45.00 美元，并给予该公司 “等权重” 评级。最后，Zacks Research 在 3 月 5 日的报告中将 Exelixis 的评级从 “强力买入” 下调至 “持有”。一位股票研究分析师对该股票给予了强力买入评级，九位给予了买入评级，十一位给予了持有评级，两位给予了卖出评级。根据 MarketBeat.com 的数据，Exelixis 的平均评级为 “持有”，共识目标价为 47.83 美元。</p>
<p><strong>查看我们关于 Exelixis 的最新报告</strong></p>
<h2>影响 Exelixis 的关键头条新闻</h2>
<ul>
<li>3 只强劲的生物技术表现者，值得关注，随着行业接近突破</li>
</ul>
<p>以下是本周影响 Exelixis 的关键新闻故事：</p>
<ul>
<li>积极情绪：第一季度业绩超预期和大规模回购——Exelixis 报告了强于预期的第一季度每股收益和净收入，并启动了一项新的 7.5 亿美元股票回购计划，管理层表示这将推动每股收益的增加，并支持股东回报。为什么 Exelixis (EXEL) 在强劲的 2026 年第一季度财报和新回购计划后上涨 9.0%</li>
<li>积极情绪：扩大回购和 zanzalintinib 的 PDUFA 时间——公司披露了 7.5 亿美元的授权，并为 zanzalintinib (ZANZA) 的结直肠癌申请概述了 12 月的 PDUFA 时间表，为未来收入增加了选择性。Exelixis 概述了 ZANZA CRC 申请的 12 月 PDUFA 时间表，同时增加了 7.5 亿美元的回购</li>
<li>积极情绪：分析师乐观和目标价上调——多家机构上调了目标价（HC Wainwright 至 56 美元，TD Cowen 至 55 美元，其他机构上调至约 50-56 美元），显示出对 cabozantinib 动能和回购驱动的每股收益的信心。Benzinga：HC Wainwright 上调目标价</li>
<li>中性情绪：投资者活动安排——管理层将在 5 月的主要投资者会议上举办炉边谈话（BofA、RBC、Stifel），提供额外的指导和问答机会，可能会影响短期情绪。Exelixis 将在 5 月即将举行的投资者会议上进行炉边谈话网络直播</li>
<li>中性情绪：分析师态度混合——摩根士丹利将其目标价上调至 50 美元，但维持了平等权重/持有的立场，Stifel 也略微上调了目标价；这些显示出谨慎的乐观，但并未达成一致的买入信心。Exelixis NASDAQ: EXEL 目标价在摩根士丹利上调至 50.00 美元</li>
<li>消极情绪：Zanzalintinib/监管和管道风险被提及——管理层和分析师在财报电话会议上提到了 ZANZA 开发和监管时间表的风险，这可能会给未来估值带来二元风险。Exelixis 财报电话会议亮点：增长和 ZANZA 风险</li>
<li>消极情绪：销售组合和收入细节——一些分析指出 cabozantinib (Cabometyx) 的增长稳健，但落后于某些预期，收入未达标显示出短期商业阻力，可能会抑制倍数扩张。EXEL 第一季度财报超出预期，结直肠癌药物成为焦点</li>
<li>消极情绪：一些分析师的谨慎观点仍然存在——富国银行的平等权重目标暗示与当前水平相比的下行风险，反映出街头观点的分歧，可能会加剧波动性。Benzinga：富国银行目标价说明</li>
</ul>
<h2>Exelixis 股票表现</h2>
<p>EXEL 周五开盘价为 46.21 美元。该公司的 50 日移动平均价格为 43.44 美元，200 日移动平均价格为 42.97 美元。Exelixis, Inc. 的 12 个月低点为 33.76 美元，12 个月高点为 49.62 美元。该公司的市值为 116.1 亿美元，市盈率为 15.35，市盈率增长比为 1.09，贝塔值为 0.38。</p>
<p>Exelixis (NASDAQ:EXEL - 获取免费报告) 最近于 5 月 5 日发布了财报。这家生物技术公司报告了每股收益 0.87 美元，超出市场共识预期的 0.75 美元 0.12 美元。Exelixis 的股本回报率为 39.89%，净利润率为 35.08%。该公司在本季度的收入为 6.1081 亿美元，而分析师预期为 6.0751 亿美元。在去年同期，该公司的每股收益为 0.55 美元。该公司本季度的收入同比增长 10.0%。整体来看，分析师预计 Exelixis, Inc. 在当前财政年度将发布每股收益 3.07 美元。</p>
<h2>关于 Exelixis</h2>
<p>(免费报告)</p>
<p>Exelixis, Inc 是一家生物技术公司，专注于小分子疗法的发现、开发和商业化，主要用于癌症治疗。该公司基于利用模式生物遗传学和高通量筛选的平台，专注于调节肿瘤生长和转移相关的关键信号通路的激酶抑制剂的研究。Exelixis 的转化研究方法旨在将新化合物从早期发现推进到临床开发和监管批准。</p>
<p>该公司最知名的产品包括 CABOMETYX® (cabozantinib)，用于治疗晚期肾细胞癌和肝细胞癌，以及 COMETRIQ® (cabozantinib) 用于转移性髓样甲状腺癌。</p>
<h2>另请参阅</h2>
<ul>
<li>五只我们更看好的股票，胜过 Exelixis</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVhFTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVhFTA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Exelixis 吗？</h2>
<p>在你考虑 Exelixis 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Exelixis 并不在名单上。</p>
<p>虽然 Exelixis 目前在分析师中获得持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

伊克力西斯

标普生物技术 3 倍做多 - Direxion

基因改革 ETF - ARK

<p>丹斯克银行（Danske Bank A S）已大幅减少对艾克利西斯（Exelixis, Inc.）的持股，减持幅度达到 99.4%，目前仅持有 1,500 股，此前在第四季度出售了 234,545 股。其他机构投资者也调整了他们的持仓，其中理查森金融服务（Richardson Financial Services）和西北互助财富管理（Northwestern Mutual Wealth Management）的持股显著增加。内部交易方面，高管们进行了大量出售。分析师对艾克利西斯的评级褒贬不一，市场共识目标价为 47.83 美元。该公司最近公布了强劲的第一季度财报，并启动了一项 7.5 亿美元的股票回购计划</p>

<p>Danske Bank A S lessened its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 99.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,500 shares of the biotechnology company's stock after selling 234,545 shares during the quarter. Danske Bank A S's holdings in Exelixis were worth $66,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>根据 Danske Bank A S 最近向证券交易委员会（SEC）提交的 13F 文件，该银行在 2023 年第四季度减少了对 Exelixis, Inc.（NASDAQ:EXEL - 免费报告）股票的持有量，减少幅度达到 99.4%。在该季度出售了 234,545 股后，Danske Bank A S 目前持有该生物技术公司 1,500 股股票。Danske Bank A S 在 Exelixis 的持股在最近一个季度末的价值为 66,000 美元。</p>
</div><ul>
<li>Exelixis Reports Solid Earnings—Are New Highs Back on the Table?</li>
</ul>
<div class="lb-trans"><ul>
<li>Exelixis 报告了稳健的收益——新的高点是否回归？</li>
</ul>
</div><p>Several other institutional investors and hedge funds also recently bought and sold shares of EXEL. Richardson Financial Services Inc. lifted its holdings in shares of Exelixis by 95.1% during the 3rd quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company's stock valued at $25,000 after buying an additional 292 shares during the last quarter. Anchor Investment Management LLC lifted its holdings in shares of Exelixis by 500.0% during the 3rd quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company's stock valued at $25,000 after buying an additional 500 shares during the last quarter. Root Financial Partners LLC acquired a new stake in shares of Exelixis during the 3rd quarter valued at about $28,000. Activest Wealth Management acquired a new stake in shares of Exelixis during the 4th quarter valued at about $32,000. Finally, Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Exelixis by 1,380.4% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 829 shares of the biotechnology company's stock valued at $34,000 after buying an additional 773 shares during the last quarter. Hedge funds and other institutional investors own 85.27% of the company's stock.</p>
<div class="lb-trans"><p>其他几家机构投资者和对冲基金最近也买卖了 EXEL 的股票。Richardson Financial Services Inc.在第三季度将其在 Exelixis 的持股增加了 95.1%。Richardson Financial Services Inc.目前拥有 599 股该生物技术公司的股票，价值 25,000 美元，此前在上个季度又购买了 292 股。Anchor Investment Management LLC 在第三季度将其在 Exelixis 的持股增加了 500.0%。Anchor Investment Management LLC 目前拥有 600 股该生物技术公司的股票，价值 25,000 美元，此前在上个季度又购买了 500 股。Root Financial Partners LLC 在第三季度获得了 Exelixis 的新股份，价值约 28,000 美元。Activest Wealth Management 在第四季度获得了 Exelixis 的新股份，价值约 32,000 美元。最后，Northwestern Mutual Wealth Management Co.在第三季度将其在 Exelixis 的持股增加了 1,380.4%。Northwestern Mutual Wealth Management Co.目前拥有 829 股该生物技术公司的股票，价值 34,000 美元，此前在上个季度又购买了 773 股。对冲基金和其他机构投资者持有该公司 85.27% 的股票。</p>
</div><h2>Insider Transactions at Exelixis</h2>
<div class="lb-trans"><h2>Exelixis 的内部交易</h2>
</div><p>In related news, SVP Brenda Hefti sold 18,669 shares of the business's stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $44.01, for a total value of $821,622.69. Following the completion of the sale, the senior vice president directly owned 96,512 shares in the company, valued at approximately $4,247,493.12. The trade was a 16.21% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Also, CFO Christopher J. Senner sold 30,617 shares of the business's stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $43.67, for a total value of $1,337,044.39. Following the completion of the sale, the chief financial officer owned 976,092 shares of the company's stock, valued at approximately $42,625,937.64. This trade represents a 3.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 362,849 shares of company stock worth $15,917,463. 2.60% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在相关消息中，SVP Brenda Hefti 于 2 月 18 日星期三出售了 18,669 股该公司的股票。股票以平均价格 44.01 美元出售，总价值为 821,622.69 美元。出售完成后，该高级副总裁直接持有 96,512 股公司股票，价值约 4,247,493.12 美元。此次交易使其持股减少了 16.21%。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过此链接获取。此外，CFO Christopher J. Senner 于 2 月 17 日星期二出售了 30,617 股该公司的股票。股票以平均价格 43.67 美元出售，总价值为 1,337,044.39 美元。出售完成后，该首席财务官持有 976,092 股公司股票，价值约 42,625,937.64 美元。此次交易使其持股减少了 3.04%。该出售的披露信息可在 SEC 文件中找到。在上个季度，内部人士共出售了 362,849 股公司股票，价值 15,917,463 美元。目前公司内部人士持有 2.60% 的股票。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师的看法</h2>
</div><ul>
<li>3 Stocks to Buy for a Soft Landing, If There Is One</li>
</ul>
<div class="lb-trans"><ul>
<li>如果有的话，3 只股票适合购买以应对软着陆</li>
</ul>
</div><p>EXEL has been the subject of several research reports. Stifel Nicolaus lifted their price target on Exelixis from $44.00 to $47.00 and gave the company a &#34;hold&#34; rating in a report on Wednesday. Weiss Ratings reiterated a &#34;buy (b)&#34; rating on shares of Exelixis in a report on Thursday, January 22nd. Truist Financial upgraded Exelixis to a &#34;strong-buy&#34; rating in a report on Monday, April 27th. Barclays lifted their price target on Exelixis from $44.00 to $45.00 and gave the company an &#34;equal weight&#34; rating in a report on Monday, April 20th. Finally, Zacks Research lowered Exelixis from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Thursday, March 5th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, Exelixis has an average rating of &#34;Hold&#34; and a consensus target price of $47.83.</p>
<div class="lb-trans"><p>EXEL 已成为几份研究报告的主题。Stifel Nicolaus 在周三将 Exelixis 的目标价从 44.00 美元上调至 47.00 美元，并给予该公司 “持有” 评级。Weiss Ratings 在 1 月 22 日的报告中重申了对 Exelixis 的 “买入（b）” 评级。Truist Financial 在 4 月 27 日的报告中将 Exelixis 的评级上调至 “强力买入”。Barclays 在 4 月 20 日的报告中将 Exelixis 的目标价从 44.00 美元上调至 45.00 美元，并给予该公司 “等权重” 评级。最后，Zacks Research 在 3 月 5 日的报告中将 Exelixis 的评级从 “强力买入” 下调至 “持有”。一位股票研究分析师对该股票给予了强力买入评级，九位给予了买入评级，十一位给予了持有评级，两位给予了卖出评级。根据 MarketBeat.com 的数据，Exelixis 的平均评级为 “持有”，共识目标价为 47.83 美元。</p>
</div><p><strong>View Our Latest Report on Exelixis</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Exelixis 的最新报告</strong></p>
</div><h2>Key Headlines Impacting Exelixis</h2>
<div class="lb-trans"><h2>影响 Exelixis 的关键头条新闻</h2>
</div><ul>
<li>3 Strong Biotech Performers To Watch As Sector Nears Breakout</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只强劲的生物技术表现者，值得关注，随着行业接近突破</li>
</ul>
</div><p>Here are the key news stories impacting Exelixis this week:</p>
<div class="lb-trans"><p>以下是本周影响 Exelixis 的关键新闻故事：</p>
</div><ul>
<li>Positive Sentiment: Q1 beat and large buyback — Exelixis reported stronger-than-expected Q1 EPS and net income and launched a new $750M share repurchase program, which management says will drive EPS accretion and supports shareholder returns. Why Exelixis (EXEL) Is Up 9.0% After Strong Q1 2026 Earnings And New Buyback Program</li>
<li>Positive Sentiment: Expanded buyback &amp; PDUFA timing for zanzalintinib — Company disclosed the $750M authorization and outlined a December PDUFA timeline for a colorectal cancer filing for zanzalintinib (ZANZA), adding optionality to future revenue. Exelixis outlines December PDUFA timeline for ZANZA CRC filing while adding $750M buyback</li>
<li>Positive Sentiment: Analyst bullishness and price-target increases — Multiple firms raised targets (HC Wainwright to $56, TD Cowen to $55 and others raising to ~$50–$56), signaling confidence in cabozantinib momentum and buyback-driven EPS. Benzinga: HC Wainwright price target raise</li>
<li>Neutral Sentiment: Investor events scheduled — Management will host fireside chats at major investor conferences in May (BofA, RBC, Stifel), providing additional opportunities for guidance and Q&amp;A that could influence near-term sentiment. Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May</li>
<li>Neutral Sentiment: Mixed analyst posture — Morgan Stanley nudged its target to $50 but kept an Equal-Weight/Hold stance, and Stifel raised a target modestly; these show cautious optimism but not unanimous buy conviction. Exelixis NASDAQ: EXEL Price Target Raised to $50.00 at Morgan Stanley</li>
<li>Negative Sentiment: Zanzalintinib/regulatory and pipeline risks flagged — Management and analysts flagged risks around ZANZA development and regulatory timelines on the earnings call, which could add binary risk to forward valuation. Exelixis Earnings Call Highlights Growth And ZANZA Risks</li>
<li>Negative Sentiment: Sales mix and revenue nuance — Some coverage notes cabozantinib (Cabometyx) growth is solid but trailing certain estimates and revenue miss signals modest near-term commercial headwinds that may temper multiple expansion. EXEL Q1 Earnings Top Estimates, Colorectal Cancer Drug in Focus</li>
<li>Negative Sentiment: Some cautious analyst views remain — Wells Fargo’s equal-weight target implies downside vs. current levels, reflecting divergent street views that can amplify volatility. Benzinga: Wells Fargo price target note</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：第一季度业绩超预期和大规模回购——Exelixis 报告了强于预期的第一季度每股收益和净收入，并启动了一项新的 7.5 亿美元股票回购计划，管理层表示这将推动每股收益的增加，并支持股东回报。为什么 Exelixis (EXEL) 在强劲的 2026 年第一季度财报和新回购计划后上涨 9.0%</li>
<li>积极情绪：扩大回购和 zanzalintinib 的 PDUFA 时间——公司披露了 7.5 亿美元的授权，并为 zanzalintinib (ZANZA) 的结直肠癌申请概述了 12 月的 PDUFA 时间表，为未来收入增加了选择性。Exelixis 概述了 ZANZA CRC 申请的 12 月 PDUFA 时间表，同时增加了 7.5 亿美元的回购</li>
<li>积极情绪：分析师乐观和目标价上调——多家机构上调了目标价（HC Wainwright 至 56 美元，TD Cowen 至 55 美元，其他机构上调至约 50-56 美元），显示出对 cabozantinib 动能和回购驱动的每股收益的信心。Benzinga：HC Wainwright 上调目标价</li>
<li>中性情绪：投资者活动安排——管理层将在 5 月的主要投资者会议上举办炉边谈话（BofA、RBC、Stifel），提供额外的指导和问答机会，可能会影响短期情绪。Exelixis 将在 5 月即将举行的投资者会议上进行炉边谈话网络直播</li>
<li>中性情绪：分析师态度混合——摩根士丹利将其目标价上调至 50 美元，但维持了平等权重/持有的立场，Stifel 也略微上调了目标价；这些显示出谨慎的乐观，但并未达成一致的买入信心。Exelixis NASDAQ: EXEL 目标价在摩根士丹利上调至 50.00 美元</li>
<li>消极情绪：Zanzalintinib/监管和管道风险被提及——管理层和分析师在财报电话会议上提到了 ZANZA 开发和监管时间表的风险，这可能会给未来估值带来二元风险。Exelixis 财报电话会议亮点：增长和 ZANZA 风险</li>
<li>消极情绪：销售组合和收入细节——一些分析指出 cabozantinib (Cabometyx) 的增长稳健，但落后于某些预期，收入未达标显示出短期商业阻力，可能会抑制倍数扩张。EXEL 第一季度财报超出预期，结直肠癌药物成为焦点</li>
<li>消极情绪：一些分析师的谨慎观点仍然存在——富国银行的平等权重目标暗示与当前水平相比的下行风险，反映出街头观点的分歧，可能会加剧波动性。Benzinga：富国银行目标价说明</li>
</ul>
</div><h2>Exelixis Stock Performance</h2>
<div class="lb-trans"><h2>Exelixis 股票表现</h2>
</div><p>EXEL opened at $46.21 on Friday. The business has a 50 day moving average price of $43.44 and a 200 day moving average price of $42.97. Exelixis, Inc. has a twelve month low of $33.76 and a twelve month high of $49.62. The firm has a market cap of $11.61 billion, a P/E ratio of 15.35, a price-to-earnings-growth ratio of 1.09 and a beta of 0.38.</p>
<div class="lb-trans"><p>EXEL 周五开盘价为 46.21 美元。该公司的 50 日移动平均价格为 43.44 美元，200 日移动平均价格为 42.97 美元。Exelixis, Inc. 的 12 个月低点为 33.76 美元，12 个月高点为 49.62 美元。该公司的市值为 116.1 亿美元，市盈率为 15.35，市盈率增长比为 1.09，贝塔值为 0.38。</p>
</div><p>Exelixis (NASDAQ:EXEL - Get Free Report) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.75 by $0.12. Exelixis had a return on equity of 39.89% and a net margin of 35.08%.The firm had revenue of $610.81 million during the quarter, compared to analyst estimates of $607.51 million. During the same period in the previous year, the company earned $0.55 EPS. The company's revenue for the quarter was up 10.0% on a year-over-year basis. As a group, analysts anticipate that Exelixis, Inc. will post 3.07 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Exelixis (NASDAQ:EXEL - 获取免费报告) 最近于 5 月 5 日发布了财报。这家生物技术公司报告了每股收益 0.87 美元，超出市场共识预期的 0.75 美元 0.12 美元。Exelixis 的股本回报率为 39.89%，净利润率为 35.08%。该公司在本季度的收入为 6.1081 亿美元，而分析师预期为 6.0751 亿美元。在去年同期，该公司的每股收益为 0.55 美元。该公司本季度的收入同比增长 10.0%。整体来看，分析师预计 Exelixis, Inc. 在当前财政年度将发布每股收益 3.07 美元。</p>
</div><h2>About Exelixis</h2>
<div class="lb-trans"><h2>关于 Exelixis</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis's translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.</p>
<div class="lb-trans"><p>Exelixis, Inc 是一家生物技术公司，专注于小分子疗法的发现、开发和商业化，主要用于癌症治疗。该公司基于利用模式生物遗传学和高通量筛选的平台，专注于调节肿瘤生长和转移相关的关键信号通路的激酶抑制剂的研究。Exelixis 的转化研究方法旨在将新化合物从早期发现推进到临床开发和监管批准。</p>
</div><p>The company's most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.</p>
<div class="lb-trans"><p>该公司最知名的产品包括 CABOMETYX® (cabozantinib)，用于治疗晚期肾细胞癌和肝细胞癌，以及 COMETRIQ® (cabozantinib) 用于转移性髓样甲状腺癌。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参阅</h2>
</div><ul>
<li>Five stocks we like better than Exelixis</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Exelixis</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVhFTA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=EXEL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Exelixis Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Exelixis 吗？</h2>
</div><p>Before you consider Exelixis, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Exelixis 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exelixis wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Exelixis 并不在名单上。</p>
</div><p>While Exelixis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Exelixis 目前在分析师中获得持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Exelixis, Inc. $EXEL Position Trimmed by Danske Bank A S

Market Beat

纽交所高增长板生物技术指数 ETF - First Trust

生物科技 ETF - VanEck Vectors

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

医疗业 ETF - SPDR

医药突破 ETF - ALPS

美国制药 ETF - iShares

医疗业 ETF - Vanguard

标普全球医疗股指数 ETF - iShares

动态生物技术与基因组 ETF - Invesco

2 倍做多纳斯达克生物技术 ETF - ProShares

丹麦银行(ADR)

Stifel Financial

Truist Financial

巴克莱银行

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

伊克力西斯公司 $EXEL 的头寸被丹麦银行 A S 减少